Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy - Abstract

Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.


Metabolic syndrome (MS) is linked to hormone-dependent cancers. Its prognostic implication in prostate cancer (PCa) is unclear. We analyzed the impact of MS in the survival of men with PCa treated surgically.

We studied patients with PCa, treated surgically between 1990 and 2007, and compared the survival of men with MS (group 1) and without MS (group 2). A subgroup analysis of those in stage pT2 was also performed. We calculated biochemical progression-free survival (bPFS) and cancer-specific survival, and the relation of clinical and pathological variables with these end-points.

65 men had MS. The 5- and 10-year bPFS in group 1 was 36 and 32% vs. 72 and 68% in group 2 (p < 0.0001). In multivariate analysis, prostate-specific antigen (p = 0.001) and MS (p < 0.0001) predicted biochemical progression/recurrence (BP/R). There was no difference in cancer-specific survival between groups (p = 0.40). Of 146 men in stage pT2, 38 had MS; group 1 men had worse 5- and 10-year bPFS (55 and 48%) than group 2 (80 and 73%; p = 0.001). In multivariate analysis, MS was the strongest predictor of BP/R (p = 0.0007).

MS is related to adverse characteristics in PCa and confers poor bPFS after radical prostatectomy. MS is independently associated to the risk of BP/R.

Written by:
Castillejos-Molina R, Rodríguez-Covarrubias F, Sotomayor M, Gómez-Alvarado MO, Villalobos-Gollás M, Gabilondo F, Feria-Bernal G.   Are you the author?

Reference: Urol Int. 2011 Aug 27. Epub ahead of print.
doi: 10.1159/000329280

PubMed Abstract
PMID: 21876327 Prostate Cancer Section